- •High body mass index (BMI) plays a key role in the development of several cancer types, including colon cancer.
- •To date, the prognostic impact of BMI in colon cancer is not fully elucidated.
- •In this post-hoc analysis of TOSCA trial, obesity with BMI ≥30 kg/m2 was an independent prognostic factor for relapse-free survival and overall survival.
- •BMI could provide additional and clinical important prognostic information in stage II/III colon cancer patients.
- •Body composition measurement should be tested to better classify visceral fat and refine risk assessment.
High body mass index (BMI) plays a key role in the development of colon cancer (CC). Our post-hoc analysis from the TOSCA trial analyzed the association between BMI and survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS) in stage II/III CC patients.
Patients and methods
Patients enrolled in the TOSCA trial between 2007-2013 with BMI data entered the study. The prognostic impact of BMI on survival outcomes was investigated through uni- and multivariable Cox regression analyses.
Overall, 1455 patients with stage II/III CC patients were included. The median follow-up was of 61.5 months; 16.1% of patients relapsed, 11.2% died and 19.5% patients relapsed or died. No impact of BMI on RFS was detected at univariate or multivariable analyses. By univariate analysis for OS, a significantly impact of a BMI > 30 kg/m2 was reported (HR [>30 vs <25] 1.57, 95% CI 1.00-2.47, p = 0.049; HR [>30 vs <30] 1.55, 95% CI 1.01-2.37, p = 0.045). Multivariable analyses did not confirm this data. In the subgroup of stage III patients, a negative survival impact of BMI was found in univariate and multivariable models both for RFS and for OS.
In our study, obesity with BMI > 30 kg/m2 was an independent prognostic factor for RFS and OS in CC patients treated with adjuvant chemotherapy, regardless of its duration (3 or 6 months). However, the prognostic impact of adiposity and body composition measurement should be considered to better classify patients with high visceral fat and refine their risk assessment.
Abbreviations:BMI (Body Mass Index)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Colorectal Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018; 68: 394-424https://doi.org/10.3322/caac.21492
- Primary and secondary prevention of colorectal cancer.Clin Med Insights Gastroenterol. 2014; 7: 33-46https://doi.org/10.4137/CGast.S14039
- Global patterns and trends in colorectal cancer incidence and mortality.Gut. 2017; 66: 683-691https://doi.org/10.1136/gutjnl-2015-310912
- Overweight, obesity, and cancer risk.Lancet Oncol. 2002; 3: 565-574https://doi.org/10.1016/s1470-2045(02)00849-5
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.Lancet. 2008; 371: 569-578https://doi.org/10.1016/S0140-6736(08)60269-X
- Fruit, Vegetables, dietary fiber, and risk of colorectal cancer.J Natl Cancer Inst. 2001; 93: 525-533https://doi.org/10.1093/jnci/93.7.525
- Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes.Clin Gastroenterol Hepatol. 2010; 8 (.e1-2): 443-450https://doi.org/10.1016/j.cgh.2010.02.001
- Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia.Dig Dis Sci. 2009; 54: 862-868https://doi.org/10.1007/s10620-008-0440-6
- Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence.Am J Clin Nutr. 2007; 86: s858-s866https://doi.org/10.1093/ajcn/86.3.858S
- Obesity and colorectal cancer.Gut. 2013; 62: 933-947https://doi.org/10.1136/gutjnl-2013-304701
Body mass index - BMI. 2019. Accessed December 24, 2019. Available at: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi
- Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from cancer and leukemia group B 89803.J Clin Oncol. 2008; 26: 4109-4115https://doi.org/10.1200/JCO.2007.15.6687
- Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.J Natl Cancer Inst. 2006; 98: 1647-1654https://doi.org/10.1093/jnci/djj442
- FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial.JCO. 2018; 36: 1478-1485https://doi.org/10.1200/JCO.2017.76.2187
- Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial.Ann Oncol. 2021; 32: 66-76https://doi.org/10.1016/j.annonc.2020.10.477
- Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.Ann Oncol. 2016; 27: 2074-2081https://doi.org/10.1093/annonc/mdw404
- Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.Ann Oncol. 2017; 28: 3110https://doi.org/10.1093/annonc/mdx021
- BMI is a risk factor for colorectal cancer mortality.Dig Dis Sci. 2017; 62: 2511-2517https://doi.org/10.1007/s10620-017-4682-z
- Impact of metformin use and diabetic status during adjuvant fluoropyrimidine-oxaliplatin chemotherapy on the outcome of patients with resected colon cancer: a TOSCA study subanalysis.Oncologist. 2019; 24: 385-393https://doi.org/10.1634/theoncologist.2018-0442
- Visceral adiposity, insulin resistance and cancer risk.Diabetol Metab Syndr. 2011; 3: 12https://doi.org/10.1186/1758-5996-3-12
- Obesity and colorectal cancer: role of adipokines in tumor initiation and progression.World J Gastroenterol. 2014; 20: 5177-5190https://doi.org/10.3748/wjg.v20.i18.5177
- Adiponectin and adiponectin receptors.Endocr Rev. 2005; 26: 439-451https://doi.org/10.1210/er.2005-0005
- Adipokines as novel biomarkers and regulators of the metabolic syndrome.Ann N Y Acad Sci. 2010; 1212: E1-E19https://doi.org/10.1111/j.1749-6632.2010.05875.x
- Chemokines in human colorectal carcinoma.Anticancer Res. 2005; 25: 3581-3584
- Interleukin-6 - a key regulator of colorectal cancer development.Int J Biol Sci. 2012; 8: 1248-1253https://doi.org/10.7150/ijbs.4614
- Metabolic syndrome and risk of death from cancers of the digestive system.Metabolism. 2010; 59: 1231-1239https://doi.org/10.1016/j.metabol.2009.11.019
- Effect of physical activity and body size on survival after diagnosis with colorectal cancer.Gut. 2006; 55: 62-67https://doi.org/10.1136/gut.2005.068189
- Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort.J Clin Oncol. 2012; 30: 42-52https://doi.org/10.1200/JCO.2011.38.0287
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.Lancet Oncol. 2008; 9: 629-635https://doi.org/10.1016/S1470-2045(08)70153-0
- Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later.Proc Nutr Soc. 2016; 75: 199-211https://doi.org/10.1017/S002966511500419X
- Body mass index and long-term outcomes in patients with colorectal cancer.Front Oncol. 2018; 8https://doi.org/10.3389/fonc.2018.00620
- Comparison of gene transcription between subcutaneous and visceral adipose tissue in Chinese adults.Endocr J. 2009; 56: 935-944https://doi.org/10.1507/endocrj.k09e-091
- Adipocytes isolated from visceral and subcutaneous depots of donors differing in BMI crosstalk with colon cancer cells and modulate their invasive phenotype.Transl Oncol. 2019; 12: 1404-1415https://doi.org/10.1016/j.tranon.2019.07.010
- The stromal-vascular fraction of adipose tissue contributes to major differences between subcutaneous and visceral fat depots.Proteomics. 2010; 10: 3356-3366https://doi.org/10.1002/pmic.201000350
- Adipose tissue endothelial cells from obese human subjects: differences among depots in angiogenic, metabolic, and inflammatory gene expression and cellular senescence.Diabetes. 2010; 59: 2755-2763https://doi.org/10.2337/db10-0398
- Impact of adiposity on staging and prognosis of colorectal cancer.Crit Rev Oncol Hematol. 2020; 145102857https://doi.org/10.1016/j.critrevonc.2019.102857
- Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer.J Clin Oncol. 2016; 34: 1339-1344https://doi.org/10.1200/JCO.2015.63.6043
- The importance of body composition in explaining the overweight paradox in cancer: counterpoint.Cancer Res. 2018; 78: 1906-1912https://doi.org/10.1158/0008-5472.CAN-17-3287
- Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS Study).Cancer Epidemiol Biomarkers Prev. 2017; 26: 1008-1015https://doi.org/10.1158/1055-9965.EPI-17-0200
- Myosteatosis and prognosis in cancer: systematic review and meta-analysis.Crit Rev Oncol Hematol. 2020; 145102839https://doi.org/10.1016/j.critrevonc.2019.102839
Published online: February 04, 2023
Accepted: January 31, 2023
Received in revised form: January 30, 2023
Received: July 13, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Published by Elsevier Inc.